E9-26787. Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Enhanced Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin

AGENCY:

Department of the Army, DoD.

ACTION:

Notice.

SUMMARY:

Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/252,675 entitled “Enhanced Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin,” filed October 18, 2009. The United States Government, as represented by the Secretary of the Army, has rights to this invention.

ADDRESSES:

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT:

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, [phone]. For licensing issues, Dr. Paul Mele, Office of Research and Technology Assessment, [phone], both at telefax [phone].

SUPPLEMENTARY INFORMATION:

The invention relates to the use of enhanced substrates for the protease activity of serotype A botulinum neurotoxin.

Brenda S. Bowen,

Army Federal Register Liaison Officer.